Biotrial Rejects French Phase I Inquiry Findings, Says Action Plan Already In Place
Executive Summary
The French health ministry has given Biotrial, the CRO that ran the disastrous Phase I FAAH inhibitor study in Rennes, one month in which to draw up an action plan to ensure that the "major failings" seen in the trial "cannot happen again." If it fails to do so it may lose its authorization to conduct clinical trials.
You may also be interested in...
Biotrial Says Will Continue To Cooperate As French Probe Manslaughter Angle in Phase I Case
French prosecutors are beginning judicial proceedings into possible manslaughter following the Phase I trial tragedy in January this year, although CRO Biotrial says the move is "a normal decision" in a complex investigation.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.